Henry Ford Health

Henry Ford Health Scholarly Commons
Dermatology Meeting Abstracts

Dermatology

9-1-2022

33463 Pooled efficacy and safety results from the DERMIS-1 and
DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by
baseline body surface area
Linda F. Stein Gold
Jerry Bagel
James Del Rosso
Lawrence J. Green
Mark Lebwohl

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_mtgabstracts

Authors
Linda F. Stein Gold, Jerry Bagel, James Del Rosso, Lawrence J. Green, Mark Lebwohl, Leon H. Kircik, Amy
Feng, Scott Snyder, Robert C. Higham, Patrick Burnett, and David R. Berk

35389
Polidocanol: A review of clinical uses
Carly Stender, BS, McGovern Medical School, The University of Texas
Health Science Center at Houston; Delfina Bur, BA, McGovern Medical
School, The University of Texas Health Science Center at Houston;
Quoc-Bao Nguyen, MD, MBA, Department of Dermatology, UTHealth McGovern
Medical School at Houston; Sirunya Silapunt, MD, Department of Dermatology,
UTHealth McGovern Medical School at Houston
Polidocanol is a nonionic detergent sclerosant that disrupts the intimal lining of
blood vessels by inducing a negative charge on endothelial surfaces. Ultimately,
thrombotic occlusion at the site of endothelial damage gives rise to endovascular
fibrosis and effective obliteration of the target vessel. Polidocanol is FDA-approved
for the treatment of uncomplicated spider veins and reticular veins in the lower
extremity. Despite its limited indication, there are numerous reports of polidocanol’s use for a variety of off-label conditions. The purpose of our study was to
describe the dermatologic clinical uses of polidocanol and to characterize efficacy
and adverse effects associated with its various applications. In a review of literature
searchable on PubMed from 2004 to 2020, polidocanol has shown efficacy in the
treatment of varicose veins, hemangioma, mucocele of the minor salivary gland,
pyogenic granuloma, lymphangioma circumscriptum, digital mucus cyst, mixed
skin ulcer, cutaneous focal mucinosis, seroma, glomovenous malformation, acne
cyst, and lymphocele. Commonly reported complications of polidocanol therapy
include pain, edema, ecchymosis, ulceration, tissue necrosis, and thrombosis of the
treated vein. Although not always first-line therapy, polidocanol may be chosen as a
treatment method for off-label conditions due to its low cost, ease of use, and
adaptability to difficult anatomic locations.
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Objective: To assess risk of respiratory tract infections (RTIs) in secukinumab
treated psoriasis patients, evaluate potential association of COVID-19 risk factors
[age [65, diabetes, obesity (BMI [40), heart and respiratory disease] with RTI
incidences and report COVID-19 cases from Periodic Safety Update Report (PSUR:
26-Dec-2019e25-Dec-2020).
Methods: Pooled data from clinical trials and postmarketing safety surveillance,
including patients who received $1 secukinumab dose, were analyzed. RTIs were
reported as exposure-adjusted incidence rates (EAIRs) per 100 patient-years.
Results: EAIR (95% CI; n) for ‘any RTI’ with secukinumab 150 mg/300 mg/150
mg+300 mg, was 42.1 (39.6e44.8; n ¼ 2117)/47.5 (46.1e48.9; n ¼ 9704)/46.6
(45.3e48.0; n ¼ 11232). EAIR for ‘viral RTI’ at same doses was 7.1 (6.2e8.0)/7.4
(6.9e7.9)/7.3 (6.9e7.7), and for ‘other RTI’ was 34.3 (32.1e36.6)/38.8
(37.5e40.1)/ 37.7 (36.6e38.9). EAIR ratios in obese versus nonobese patients for
viral pharyngitis/streptococcal pharyngitis/bacterial sinusitis with secukinumab
150 mg+300 mg were 4.2 (1.2e15.1)/3.4 (1.7e7.0)/6.9 (2.1e22.3), respectively.
Strong associations with other COVID-19 risk factors were not observed. Of 952
COVID-19 cases retrieved, outcome was reported in 416 cases: completely
recovered (n ¼ 101), recovered with sequelae (n ¼ 7), condition improving (n ¼
68), unchanged (n ¼ 165), deteriorated (n ¼ 54) and fatal (n ¼ 21). Overall, 221
cases were confounded by risk factors (age [65, comorbidities, or concomitant use
of immunosuppressant). Of 21 COVID-19 fatal cases, 14 had risk factors (age [65,
comorbidities and smoking) whereas 7 had limited information.
Conclusion: RTIs in secukinumab treated psoriasis patients from pooled clinical
trials and postmarketing surveillance data were consistent with previous publications. In this analysis, obesity increased the risk for RTIs. COVID-19 cases in the
PSUR revealed no new safety signals regarding known risk of ‘infections and
infestations.’
Commercial Disclosure: This investigation was sponsored by Novartis Pharma
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Roflumilast cream 0.3% is a selective and potent phosphodiesterase-4 inhibitor
under investigation as a once-daily treatment for psoriasis. Here we describe pooled
efficacy and safety results from 2 identical phase 3 randomized controlled trials of
roflumilast cream (DERMIS-1: NCT04211363 and DERMIS-2: NCT04211389)
analyzed by baseline body surface area (BSA) affected ( 10%). Patients ($2 years)
with psoriasis involving 2-20% BSA were randomized to roflumilast (n ¼ 576) or
vehicle (n ¼ 305) for 8 weeks. Overall, significantly more roflumilast- vs. vehicletreated patients achieved the primary efficacy endpoint of Investigator Global
Assessment (IGA) Success (Clear or Almost Clear IGA status plus $2-grade
improvement from baseline) at Week 8 (39.9% vs. 6.5%; P \ .0001). More
roflumilast-treated patients achieved IGA Success at Week 8 with generally
consistent rates (36.5%-46.7% with roflumilast vs. 1.8%-8.5% with vehicle) across
all BSA categories (P \ .0001 for all). Differences favoring roflumilast were also
observed for percentages achieving 75% reduction in Psoriasis Area Severity Index
(38.1%-47.8% with roflumilast vs. 1.8%-9.4% with vehicle) across all BSA categories.
Percentages with baseline Worst Itch-Numeric Rating Scale $4 achieving a 4-point
reduction favored roflumilast (P # .0001 for all BSA subgroups). Overall incidence of
treatment-emergent adverse events (TEAE), serious adverse events, and TEAEs
leading to discontinuation were low with similar rates between roflumilast and
vehicle. Local tolerability was highly favorable on patient and investigator
assessments. Once-daily roflumilast cream 0.3% provided superior improvement
across multiple efficacy endpoints and favorable safety and tolerability in patients
with psoriasis in 2 phase 3 trials regardless of BSA affected.
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A 52-year-old woman presented with 1-week history of an asymptomatic eruption
on the right knee. This started as blanched patches which progressed over a few
days to raised urticarial papules. Prior to the onset of the eruption, she had been
using a cold therapy device on this knee for three weeks after arthroscopy and
medial meniscus repair. On examination, there were smooth indurated round
papules localized to the right anterior knee. A punch biopsy was obtained revealing
a superficial and deep perivascular lymphocytic infiltrate extending into the
subcutis, consistent with cold panniculitis. Cold panniculitis refers to inflammation
of the fat following exposure to very cold temperatures. It is most common in the
cheeks of young children but has rarely been reported in adults, including in female
equestrians and after use of ice packs for chronic lower back pain. There has also
been a report of cold panniculitis after use of a cold device after shoulder surgery.
Treatment frequently involves removing the source of thermal injury. Our patient
was instructed to stop using her cold therapy device and over time her lesions
resolved. Given the development and increased availability of such devices, it is
possible a similar clinical picture may present more frequently in dermatology
clinics in the future.
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